{
  "ticker": "VHL",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02964916",
  "id": "02964916",
  "pages": 3,
  "price_sensitive": true,
  "date": "20250702",
  "time": "0928",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250702/pdf/06lcjvq24lgtv8.pdf",
  "summary": "- **Capital Raising Announcement**:  \n  - **Structure**: Placement to sophisticated/professional/institutional investors.  \n  - **Amount Raised**: AUD 11 million (before expenses).  \n  - **Issue Price**: AUD 0.03 per share (16.2% discount to 5-day VWAP of AUD 0.0358).  \n  - **Use of Proceeds**: Clinical operations, technology enhancements, sales/marketing, working capital.  \n  - **Funding Runway**: Expected to support operations until cash flow breakeven in H2 FY2026.  \n\n- **Director Participation**:  \n  - CEO and Chairman to invest AUD 500,000 combined (subject to shareholder approval).  \n\n- **Key Investor Catalyst**:  \n  - Execution of expanded TPAC agreement and client expansion drove strong institutional demand (USD 4.5M from a key investor).  \n\n*Omitted: Boilerplate, forward-looking statements, operational background.*",
  "usage": {
    "prompt_tokens": 2277,
    "completion_tokens": 200,
    "total_tokens": 2477,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-01T23:40:55.537665"
}